Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Uncategorized

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain